JP2014512333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512333A5 JP2014512333A5 JP2013549539A JP2013549539A JP2014512333A5 JP 2014512333 A5 JP2014512333 A5 JP 2014512333A5 JP 2013549539 A JP2013549539 A JP 2013549539A JP 2013549539 A JP2013549539 A JP 2013549539A JP 2014512333 A5 JP2014512333 A5 JP 2014512333A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- metformin
- composition according
- compound
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- MBMBGCFOFBJSGT-KUBAVDMBSA-N Docosahexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 229960004363 doconexent Drugs 0.000 claims 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 5
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 5
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 5
- 229960003105 Metformin Drugs 0.000 claims 4
- 229960005135 Eicosapentaenoic Acid Drugs 0.000 claims 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N Eicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 3
- 210000002966 Serum Anatomy 0.000 claims 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 3
- 239000012458 free base Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000011541 reaction mixture Substances 0.000 claims 3
- 150000003626 triacylglycerols Chemical class 0.000 claims 3
- 206010003119 Arrhythmia Diseases 0.000 claims 2
- 206010007521 Cardiac arrhythmias Diseases 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 208000010125 Myocardial Infarction Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 208000005846 Cardiomyopathy Diseases 0.000 claims 1
- 206010014486 Elevated triglyceride Diseases 0.000 claims 1
- 208000006575 Hypertriglyceridemia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 201000008031 cardiomyopathy Diseases 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 230000001747 exhibiting Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000012299 nitrogen atmosphere Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Claims (10)
- メトホルミンとドコサヘキサエン酸との塩、またはメトホルミンとエイコサペンタエン酸およびドコサヘキサエン酸の混合物との塩である、化合物。
- 請求項1に記載の化合物、および薬学的に許容可能な担体、ビヒクル、または希釈剤を含む、医薬組成物。
- 請求項1に記載の化合物または請求項2に記載の医薬組成物を含む単位剤形、使用のための指示、および前記単位剤形を収容するための少なくとも1つの容器を含むキット。
- 糖尿病、トリグリセリドの上昇、前糖尿病、肥満、心不整脈、心筋症または心筋梗塞から選択される哺乳類の症状を治療するための、請求項2に記載の医薬組成物。
- a)好適なメトホルミン塩からメトホルミンの遊離塩基を新しく調製すること;およびb)新しく調製したメトホルミンの遊離塩基を、ドコサヘキサエン酸、またはエイコサペンタエン酸およびドコサヘキサエン酸の混合物と、1℃から60℃の間の温度で反応させることを含む、請求項1に記載の化合物を製造するための方法。
- 治療が必要である被験者の血清トリグリセリドを低下するための、請求項2に記載の医薬組成物。
- 前記被験者が、200mg/dLを超える血清トリグリセリド濃度を有する、請求項6に記載の医薬組成物。
- 前記被験者が高トリグリセリド血症である、請求項6に記載の医薬組成物。
- 前記被験者が、発展中の糖尿病、前糖尿病状態、肥満、心不整脈、心筋梗塞、および高血清トリグリセリド濃度に起因する脳卒中を示す、またはこれらのリスクを有する被験者からなる群からさらに選択される、請求項6に記載の医薬組成物。
- 以下の工程:
アセトニトリル中のメトホルミン遊離塩基の濃縮溶液に、ドコサヘキサエン酸、またはエイコサペンタエン酸およびドコサヘキサエン酸の混合物を室温で滴下して加える工程、
反応混合物を、光から防護された容器中で、1時間室温で撹拌する工程、
前記反応混合物を、1時間、0℃で冷却する工程、および
冷却された前記反応混合物を窒素雰囲気下で濾過し、粉末になるまで乾燥させる工程、
を含む、請求項1に記載の化合物を製造する方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161461113P | 2011-01-12 | 2011-01-12 | |
US61/461,113 | 2011-01-12 | ||
US13/348,265 | 2012-01-11 | ||
US13/348,265 US20120178813A1 (en) | 2011-01-12 | 2012-01-11 | Lipid-lowering antidiabetic agent |
PCT/US2012/021070 WO2012097144A1 (en) | 2011-01-12 | 2012-01-12 | Lipid-lowering antidiabetic agent |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014512333A JP2014512333A (ja) | 2014-05-22 |
JP2014512333A5 true JP2014512333A5 (ja) | 2015-03-12 |
JP5911514B2 JP5911514B2 (ja) | 2016-04-27 |
Family
ID=46455756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013549539A Expired - Fee Related JP5911514B2 (ja) | 2011-01-12 | 2012-01-12 | 脂質低下抗糖尿病薬 |
Country Status (12)
Country | Link |
---|---|
US (4) | US20120178813A1 (ja) |
EP (1) | EP2663186A4 (ja) |
JP (1) | JP5911514B2 (ja) |
KR (1) | KR20140092228A (ja) |
CN (1) | CN103533833B (ja) |
AU (1) | AU2012205547B2 (ja) |
BR (1) | BR112013017845A2 (ja) |
CA (1) | CA2824192A1 (ja) |
EA (1) | EA201391028A1 (ja) |
IL (1) | IL227346A0 (ja) |
MX (1) | MX2013008131A (ja) |
WO (1) | WO2012097144A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120178813A1 (en) | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
US8765811B2 (en) | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
WO2014011814A1 (en) * | 2012-07-10 | 2014-01-16 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
US9382187B2 (en) | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
WO2014080307A2 (en) * | 2012-11-21 | 2014-05-30 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
WO2014195810A2 (en) * | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
EP3004049B1 (en) * | 2013-06-04 | 2018-09-05 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
WO2015022613A1 (en) * | 2013-08-11 | 2015-02-19 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
EP3140316A1 (en) * | 2014-05-05 | 2017-03-15 | Thetis Pharmaceuticals LLC | Compositions and methods relating to ionic salts of peptides |
DK3157936T3 (en) | 2014-06-18 | 2019-02-04 | Thetis Pharmaceuticals Llc | MINERAL AMINO ACID ACID COMPLEXES OF ACTIVE SUBSTANCES |
US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
WO2016132186A1 (en) * | 2015-02-20 | 2016-08-25 | Mohan M Alapati | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome |
US9371276B1 (en) * | 2015-03-21 | 2016-06-21 | Mohan Murali Alapati | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome |
EP3454907B1 (en) | 2016-06-03 | 2020-07-22 | Thetis Pharmaceuticals LLC | Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation |
EP3648748A1 (en) | 2017-07-06 | 2020-05-13 | Evonik Operations GmbH | Enteric coated solid dosage form comprising omega-3 fatty acid amino acid salts |
JP7050148B2 (ja) | 2017-08-15 | 2022-04-07 | エボニック オペレーションズ ゲーエムベーハー | オメガ-3脂肪酸アミノ酸塩の有効成分含有量が高い錠剤 |
WO2019120111A1 (zh) * | 2017-12-18 | 2019-06-27 | 镇学初 | 二甲双胍盐在治疗脑梗死中的用途 |
CN114206135A (zh) | 2019-08-08 | 2022-03-18 | 赢创运营有限公司 | 用于生产多不饱和脂肪酸盐的下游工艺 |
US20220287345A1 (en) | 2019-08-08 | 2022-09-15 | Evonik Operations Gmbh | Solubility enhancement of poorly soluble actives |
CN113105367B (zh) * | 2021-03-30 | 2022-08-02 | 广州大学 | 一类二甲双胍盐及其制备方法和应用 |
CN116999398A (zh) * | 2022-06-30 | 2023-11-07 | 山东海赜生物科技有限公司 | 一种口服组合物 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
ATE345122T1 (de) | 2000-02-04 | 2006-12-15 | Takeda Pharmaceutical | Stabile emulsionszubereitungen |
US6491950B1 (en) | 2000-08-07 | 2002-12-10 | Kos Pharmaceuticals, Inc. | Controlled release pharmaceutical composition |
US6667064B2 (en) | 2000-08-30 | 2003-12-23 | Pilot Therapeutics, Inc. | Composition and method for treatment of hypertriglyceridemia |
US6689385B2 (en) * | 2000-11-03 | 2004-02-10 | Chronorx Llc | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus |
FR2818906B1 (fr) * | 2000-12-29 | 2004-04-02 | Dospharma | Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine |
DE10102050A1 (de) | 2001-01-17 | 2002-07-18 | Basf Ag | Zubereitung zur Verbesserung der Nahrungsverwertung |
US6881854B2 (en) | 2001-03-29 | 2005-04-19 | Basf Aktiengesellschaft | Conjugated unsaturated glyceride mixtures and a method for producing the same |
EP1429602B1 (en) | 2001-08-31 | 2009-12-16 | Rutgers, The State University Of New Jersey | Methods for treating disorders using plant extracts |
ITMI20012384A1 (it) | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
AU2003211131A1 (en) * | 2002-02-14 | 2003-09-04 | Sonus Pharmaceuticals, Inc. | Metformin salts of lipophilic acids |
US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
US7399488B2 (en) * | 2002-07-05 | 2008-07-15 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
EP2384750A1 (en) * | 2002-09-27 | 2011-11-09 | Martek Biosciences Corporation | Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid |
ITMI20022394A1 (it) | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
EP1605781A1 (en) * | 2003-03-18 | 2005-12-21 | Novartis AG | Compositions comprising fatty acids and amino acids |
EP1510208A1 (en) | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
US20080045559A1 (en) | 2003-10-29 | 2008-02-21 | Sonus Pharmaceuticals, Inc. | Tocopherol-modified therapeutic drug compounds |
DE602004027936D1 (de) | 2003-10-29 | 2010-08-12 | Sonus Pharmaceutical Inc | Tocopherolmodifizierte therapeutische arzneimittelverbindung |
AU2004285532A1 (en) * | 2003-10-31 | 2005-05-12 | Alza Corporation | Administration of levodopa and carbidopa |
EP1708707A1 (en) | 2004-01-22 | 2006-10-11 | Neurosearch A/S | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist |
WO2005118612A1 (en) | 2004-06-04 | 2005-12-15 | Sonus Pharmaceuticals, Inc. | Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs |
JP5491697B2 (ja) * | 2004-10-15 | 2014-05-14 | フォトンズ コーポレイション リミテッド | 高レベルオメガ−3および低レベル飽和脂肪酸を含む組成物 |
WO2006046156A2 (en) | 2004-10-29 | 2006-05-04 | Joan Campbell-Tofte | Anti-diabetic extract isolated from rauvolfia vomitoria and citrus aurantium, and methods of using same |
US20080200533A1 (en) | 2005-07-04 | 2008-08-21 | Ramu Krishnan | Drug or Pharmaceutical Compounds and a Preparation Thereof |
US7666898B2 (en) | 2005-11-03 | 2010-02-23 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors |
US20070213298A1 (en) * | 2006-02-07 | 2007-09-13 | Universitetet I Oslo | Omega 3 |
JP2009526747A (ja) | 2006-02-16 | 2009-07-23 | 武田薬品工業株式会社 | 環状アミン化合物および高血圧の予防・治療のための用途 |
US20090047340A1 (en) | 2006-03-29 | 2009-02-19 | Guilford F Timothy | Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis |
CN101522658A (zh) | 2006-06-16 | 2009-09-02 | 因迪基恩药物公司 | 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐 |
CN101535238A (zh) | 2006-11-01 | 2009-09-16 | 普罗诺瓦生物医药挪威公司 | 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质 |
WO2008053340A1 (en) * | 2006-11-03 | 2008-05-08 | Pronova Biopharma Norge As | A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent |
US20100105773A1 (en) * | 2006-11-09 | 2010-04-29 | The Children's Medical Center Corporation | Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization |
WO2008093984A1 (en) * | 2007-01-29 | 2008-08-07 | Hanall Pharmaceutical Company. Ltd | N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same |
US20090227560A1 (en) | 2007-04-27 | 2009-09-10 | Takanobu Kuroita | Substituted imidazole compound and use thereof |
CL2008001163A1 (es) | 2007-04-27 | 2008-12-19 | Takeda Pharmaceutical | Compuestos derivados de 1h-imidazo-4-il(piperazibn) metanona, inhibidores de renina superior, composicion farmaceutica que comprende a dichos compuestos; y uso de los compuestos para el tratamiento o prevencion de la hipertension. |
US20090054513A1 (en) * | 2007-08-22 | 2009-02-26 | Response Scientific, Inc. | Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease |
JP5292404B2 (ja) * | 2007-09-21 | 2013-09-18 | ハンオル バイオファーマ カンパニー,リミテッド | N,n−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物 |
WO2009051112A1 (ja) | 2007-10-15 | 2009-04-23 | Takeda Pharmaceutical Company Limited | アミド化合物およびその用途 |
ES2645588T3 (es) | 2008-05-05 | 2017-12-05 | Oramed Ltd. | Métodos y composiciones para la administración oral de exenatida |
EA201301040A1 (ru) | 2008-06-19 | 2014-01-30 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение и его применение |
AU2010241567B2 (en) * | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
US20110052678A1 (en) | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
US20120178813A1 (en) | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
CA2916208A1 (en) | 2012-06-17 | 2013-12-27 | Matinas Biopharma, Inc. | Omega-3 pentaenoic acid compositions and methods of use |
-
2012
- 2012-01-11 US US13/348,265 patent/US20120178813A1/en not_active Abandoned
- 2012-01-12 EP EP12734013.1A patent/EP2663186A4/en not_active Withdrawn
- 2012-01-12 JP JP2013549539A patent/JP5911514B2/ja not_active Expired - Fee Related
- 2012-01-12 AU AU2012205547A patent/AU2012205547B2/en not_active Ceased
- 2012-01-12 CA CA2824192A patent/CA2824192A1/en not_active Abandoned
- 2012-01-12 BR BR112013017845A patent/BR112013017845A2/pt not_active IP Right Cessation
- 2012-01-12 WO PCT/US2012/021070 patent/WO2012097144A1/en active Application Filing
- 2012-01-12 EA EA201391028A patent/EA201391028A1/ru unknown
- 2012-01-12 KR KR20137018679A patent/KR20140092228A/ko not_active Application Discontinuation
- 2012-01-12 CN CN201280005222.1A patent/CN103533833B/zh not_active Expired - Fee Related
- 2012-01-12 MX MX2013008131A patent/MX2013008131A/es not_active Application Discontinuation
-
2013
- 2013-06-21 US US13/923,829 patent/US8901107B2/en not_active Expired - Fee Related
- 2013-07-04 IL IL227346A patent/IL227346A0/en unknown
- 2013-12-20 US US14/136,843 patent/US9012507B2/en not_active Expired - Fee Related
-
2014
- 2014-10-27 US US14/524,721 patent/US9216951B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2014512333A5 (ja) | ||
JP2015523382A5 (ja) | ||
JP7443057B2 (ja) | (S)-N-(5-((R)-2-(2,5-ジフルオロフェニル)ピロリジン-1-イル)-ピラゾロ[1,5-a]ピリミジン-3-イル)-3-ヒドロキシピロリジン-1-カルボキサミドの調製 | |
Köppen et al. | Solvent-dependent formation of three new Bi-metal–organic frameworks using a tetracarboxylic acid | |
RU2014110399A (ru) | Кристаллические формы вгс протеазного ингибитора | |
JP2013032389A5 (ja) | ||
JP2019512474A (ja) | シアノ置換インドール化合物およびlsd1阻害剤としてのその使用 | |
JP2013525444A5 (ja) | ||
WO2012076466A2 (de) | Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung | |
Sun et al. | Strengthening π–π interactions while suppressing Csp2–H··· π (T-shaped) interactions via perfluoroalkylation: A crystallographic and computational study that supports the beneficial formation of 1-D π–π stacked aromatic materials | |
JP2013518107A5 (ja) | ||
JP2012512197A5 (ja) | ||
JP2011037841A5 (ja) | ||
Croitor et al. | Nine Mn (II), Zn (II) and Cd (II) mixed-ligand coordination networks with rigid dicarboxylate and pyridine-n-aldoxime ligands: Impact of the second ligand in the structures’ dimensionality and solvent capacity | |
JP2012107014A5 (ja) | ||
Choquesillo-Lazarte et al. | Halogen bonded cocrystals of active pharmaceutical ingredients: pyrazinamide, lidocaine and pentoxifylline in combination with haloperfluorinated compounds | |
JP2013541592A5 (ja) | ||
TW201216957A (en) | Biarylamide derivative or a pharmaceutically acceptable salt thereof | |
US9394298B2 (en) | Pyrroloquinoline quinone tetraalkali salt and crystal thereof, methods for producing these, and composition | |
RU2019138773A (ru) | Производство транс-[тетрахлорбис(1h-индазол)рутената(iii)] и его композиций | |
Božić et al. | Synthesis, characterization and antiproliferative activity of transition metal complexes with 3-(4, 5-diphenyl-1, 3-oxazol-2-yl) propanoic acid (oxaprozin) | |
PE20131327A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen | |
JP2012176989A5 (ja) | ||
JP2018509421A5 (ja) | ||
WO2014008379A3 (en) | Diamine and meglumine salt forms of fatty acids |